China’s Eddingpharm Deal A Fresh Start For Ablynx’s Ozoralizumab
This article was originally published in PharmAsia News
Ablynx has signed a deal with Chinese company Eddingpharm for certain Asian rights to its rheumatoid arthritis drug ozoralizumab, marking a fresh start for the anti-TNF nanobody after Pfizer backed out of a global deal in 2011.
You may also be interested in...
Oncology focused startup EOC Pharma expects to develop an “exciting” pipeline in two years via the licensing model. The company is also seeking “constant” financing as it advances three drug candidates into the next stage in 2018, EOC CEO Xiaoming Zou tells Scrip in an interview.
With no currently approved treatment for agitation in Alzheimer’s disease, analysts see a solid revenue opportunity for Rexulti. The companies plan to file a supplemental NDA later this year.
The Swiss biotech says the ERADICATE trial shows areas of differentiation for the antibiotic, like utility in pneumonia and across gram-negative and gram-positive bacteria.